quantamatrix 产品代理
quantamatrix 产品代理
QuantaMatrix成立于2010年，是一家体外诊断公司。它是首尔国立大学生物光子学和纳米工程实验室（BiNEL）的衍生产品，由首尔国立大学电气和计算机工程系教授权成勋博士领导。我们通过提供治疗败血症的直接快速抗菌药物敏感性试验（dRASTTM），解决了抗生素滥用问题，并推广了最佳抗菌药物处方。
脓毒症是一种危及生命的疾病，死亡率超过40%，治疗每延迟1小时，死亡风险就会增加7%至9%。仅在美国，每年的社会经济成本约为270亿美元；因此，最佳抗菌剂的处方对于防止菌血症发展为败血症至关重要。传统的抗生素敏感性测试（AST）是在血液培养、纯培养、鉴定（ID）和敏感性测试之后进行的，医院需要60多小时或三个工作日来进行。缩短最佳治疗时间与患者生存率直接相关。
Sepsis
dRASTTM
Tuberculosis
QDSTTM
Alzheimer’s Disease
QPLEXTM Alz plus assay
Cardiovascular
Quanti9TM & QuantiGalTM
QuantaMatrix was founded in 2010 as an in-vitro diagnostics company. It is a spin-off from Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University led by Dr. Sunghoon Kwon, professor of Electrical and Computer Engineering Department at Seoul National University. We resolve antibiotics misuse issue and promote optimal antimicrobial prescription by providing direct Rapid Antimicrobial Susceptibility Testing (dRASTTM) for treating sepsis.
Sepsis is a life-threatening condition with mortality rate of more than 40% and every 1-hour delay in treatment increases mortality risk by seven to nine percent. In the U.S. alone, the annual socioeconomic cost is approximately $27 billion; therefore, the prescription of optimal antimicrobial is essential to preventing the progression of bacteremia to sepsis. Conventional antimicrobial susceptibility testing (AST), which follows blood culture, pure culture, identification (ID), and susceptibility testing, takes over 60 hours, or three business days for hospitals to conduct. Minimizing the time to optimal treatment is directly linked to patient survival.
dRASTTM, our rapid antimicrobial susceptibility test solution, decrease the time to optimal treatment by 30-50 hours. By decreasing the time of empirical treatment through dRASTTM, we can expect more effective treatment against bacterial infection and prevent antimicrobial resistance by reducing the prescription of inappropriate antibiotics. Moreover, the shortened treatment time improves the profitability of hospitals with shorter length of stay in hospital. Thus, dRASTTM possesses significant clinical and socioeconomic benefits.
In our pipeline, we have competitive products such as QDSTTM, a rapid drug susceptibility test for Mycobacterium tuberculosis; QPLEXTM Alz plus assay, early detection of an Alzheimer's disease; or Quanti9TM & QuantiGalTM, a prognostic prediction kit for Cardiovascular diseases in research use only cases. We aim to continue our growth as the most innovative in vitro diagnostics company in fields of microbiology, molecular biology, and immunoassay.
